Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113118
Chunk: 59

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 59
---
 for equity classification under ASC 815, including whether the instruments are indexed to the Company’s
own common stock and whether the instrument holders could potentially require “net cash settlement” in a circumstance outside
of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional
judgment, was conducted at the time of warrant issuance and as of each subsequent period end date while the instruments are outstanding.

Public and Private Placement Warrants (Successor)

As of September 30, 2025
and December 31, 2024, there were 4,596 Public and Private Placement Warrants outstanding, each with a right to purchase one share of
Common Stock for $23,000. The Public and Private Placement Warrants became exercisable 30 days after the Merger. No warrants will be exercisable
for cash unless the Company has an effective and current registration statement covering the Common Stock issuable upon exercise of the
warrants and a current prospectus relating to such Common Stock. The Public and Private Placement Warrants were registered under a resale
registration statement on Form S-1 (File No. 333-279156), which was declared effective by the Securities and Exchange Commission on July
5, 2024.

Notwithstanding the foregoing,
Public and Private Placement Warrant holders may, during any period when the Company shall have failed to maintain an effective registration
statement, exercise warrants on a cashless basis pursuant to the exemption provided by Section 3(a)(9) of the Securities Act, provided
that such exemption is available. If that exemption, or another exemption, is not available, holders will not be able to exercise their
warrants on a cashless basis. The Public and Private Placement Warrants will expire five years after the Merger or earlier upon redemption
or liquidation.

Once the warrants became
exercisable, the Company may, with 30 days prior notice, redeem the Public Warrants in whole and not in part, at a price of $0.20 per
warrant if the shares underlying the warrants are registered and if the closing price of Common Stock equals or exceeds $36,000.00 for
20 of the prior 30 trading days. If the Company calls the Public Warrants for redemption, management will have the option to require all
holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement.

The exercise price and number
of shares of Common